Document is current
Any future updates will be listed below
-
Authors
Fredrick, Thomas
Maselli, Daniel
Vargas, Eric
Wooley, Chase
Gala, Khushboo
Anazco, Diego
Ciotlos, Serban
O’Connor, Timothy
Abu Dayyeh, Barham
McGowan, Christopher
Acosta, Andres
- License Information
-
More Information
Article History
Received: 11 September 2025
Revised: 2 February 2026
Accepted: 25 March 2026
First Online: 7 May 2026
Declarations
:
: This study was conducted with approval from the institutional IRB. Data was stored on secure internal servers at the performing institution. Genetic samples, once analyzed, were subsequently destroyed. All participants signed informed consent forms to participate in the study.
: Daniel B. Maselli was previously a consultant for Apollo Endosurgery. Barham Abu Dayyeh reports consulting and research support from Boston Scientific. Consulting for Olympus and research support from Merit Medical and ERBE. Christopher E. McGowan was previously a consultant for Apollo Endosurgery and is now a consultant for Boston Scientific, and he has received research support from Erbe. Dr. Acosta is a stockholder in Gila Therapeutics, Phenomix Sciences; he served as a consultant for Rhythm Pharmaceuticals, General Mills, and Amgen Pharmaceuticals. The remaining authors disclose no conflicts.
